Mineralys Therapeutics (MLYS) is drawing attention as it progresses its drug candidate Lorundrostat. The company's efforts in this area are generating interest among biotech investors.
- Progress in Lorundrostat development
- Potential interest for biotech investors
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article